Asset Details
Do you wish to reserve the book?
Targeting of SKP2 to combat drug resistance in multiple myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting of SKP2 to combat drug resistance in multiple myeloma
Do you wish to request the book?
Targeting of SKP2 to combat drug resistance in multiple myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting of SKP2 to combat drug resistance in multiple myeloma
2025
Overview
Multiple myeloma (MM) is an incurable plasma cell malignancy in which drug resistance remains a significant limitation to treatment. SKP2, the substrate-recognition component of the SCF-SKP2 ubiquitin-protein ligase complex, plays a critical role in the progression of various cancers, including MM. Targeting
SKP2
as a therapeutic strategy offers a promising avenue for combating drug resistance in myeloma. Here, we show that
SKP2
expression increases as the disease progresses from pre-myeloma to newly diagnosed and relapsed stages. Gene set enrichment analysis (GSEA) and immunoblotting further revealed that SKP2 inhibition by the preclinical chemical inhibitor SkpinC1 leads to decreased STAT3 inflammatory signalling and c-MYC expression in myeloma cells. When tested in
SKP2
-overexpressing cells, SkpinC1 retained the ability to reduce activated STAT3, c-MYC, and c-MAF protein levels to impair cell growth and induce apoptosis. Furthermore, SkpinC1 synergistically enhanced the sensitivity of patient myeloma samples to bortezomib. Taken together, these findings underline the potential of
SKP2
inhibition to overcome drug resistance in MM.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/80
/ Antineoplastic Agents - pharmacology
/ c-MAF
/ c-MYC
/ Cell Proliferation - drug effects
/ Drug Resistance, Neoplasm - drug effects
/ Gene Expression Regulation, Neoplastic - drug effects
/ Gene set enrichment analysis
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - metabolism
/ Multiple Myeloma - pathology
/ Patients
/ Plasmids
/ Proteins
/ Proto-Oncogene Proteins c-myc - metabolism
/ Reagents
/ S-Phase Kinase-Associated Proteins - antagonists & inhibitors
/ S-Phase Kinase-Associated Proteins - genetics
/ S-Phase Kinase-Associated Proteins - metabolism
/ Science
/ Signal Transduction - drug effects
/ Software
/ STAT3
